Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HIDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: Various implementations include an extended repeated-use table cover device. The device includes a roller, a non-silicone mat, a disinfecting enclosure, a table mount, and a winding mechanism. An outer surface of the roller is coupled to a first mat end such that rotation of the roller about a roller axis causes the mat to wind around the outer surface of the roller. An outer surface of the disinfecting enclosure defines an opening extending from the outer surface to a cavity defined by an inner surface of the disinfecting enclosure. The roller is disposed within the cavity, and the mat is extendable through the opening. The winding mechanism is for rotating the roller from an extended position to a retracted position. The mat is durable enough to be used for at least three months under expected standard use without needing to be replaced.

Abstract: Various implementations include an extended repeated-use table cover device. The device includes a roller, a non-silicone mat, a disinfecting enclosure, a table mount, and a winding mechanism. An outer surface of the roller is coupled to a first mat end such that rotation of the roller about a roller axis causes the mat to wind around the outer surface of the roller. An outer surface of the disinfecting enclosure defines an opening extending from the outer surface to a cavity defined by an inner surface of the disinfecting enclosure. The roller is disposed within the cavity, and the mat is extendable through the opening. The winding mechanism is for rotating the roller from an extended position to a retracted position. The mat is durable enough to be used for at least three months under expected standard use without needing to be replaced.

Abstract: Various implementations include an extended repeated-use table cover device. The device includes a roller, a non-silicone mat, an enclosure, a table mount, and a winding mechanism. An outer surface of the roller is coupled to a first mat end such that rotation of the roller about a roller axis causes the mat to wind around the outer surface of the roller. An outer surface of the enclosure defines an opening extending from the outer surface to a cavity defined by an inner surface of the enclosure. The roller is disposed within the cavity, and the mat is extendable through the opening. The cavity is fillable with a cleaning liquid. The winding mechanism is for rotating the roller from an extended position to a retracted position. The mat is durable enough to be used for at least three months under expected standard use without needing to be replaced.

Abstract: Various implementations include an extended repeated-use table cover device. The device includes a roller, a non-silicone mat, an enclosure, a table mount, and a winding mechanism. An outer surface of the roller is coupled to a first mat end such that rotation of the roller about a roller axis causes the mat to wind around the outer surface of the roller. An outer surface of the enclosure defines an opening extending from the outer surface to a cavity defined by an inner surface of the enclosure. The roller is disposed within the cavity, and the mat is extendable through the opening. The cavity is fillable with a cleaning liquid. The winding mechanism is for rotating the roller from an extended position to a retracted position. The mat is durable enough to be used for at least three months under expected standard use without needing to be replaced.